ADVA
27.4.2021 09:02:12 CEST | Business Wire | Press release
ADVA (FSE: ADV) today launched its OSA 5405-MB , the industry’s first ultra-compact outdoor PTP grandmaster clock with multi-band GNSS receiver and integrated antenna. Part of the OSA 5405 Series of smart synchronization devices for indoor or outdoor deployment, the OSA 5405-MB ensures timing accuracy by eliminating the impact of ionospheric delay variation. This empowers communication service providers (CSPs) and enterprises to deliver the nanosecond precision needed for 5G fronthaul and other emerging time-sensitive applications. The multi-band GNSS receiver and integrated antenna enable the OSA 5405-MB to meet PRTC-B accuracy requirements (+/-40nsec) even in challenging conditions. For the first time, the technology is available in an edge timing device with minimal footprint, helping operators achieve unprecedented accuracy and reliability as they roll out wide-spread small cell networks.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210427005060/en/
“Our multi-band, multi-constellation GNSS receiver provides an extremely cost-efficient way to achieve PRTC-B UTC-traceable network timing with the levels of accuracy needed for next-generation use cases. By adding this technology to our versatile, small-form-factor OSA 5405 Series, we’re offering a route to precision synchronization at the network access without significant investment,” said Gil Biran, general manager, Oscilloquartz, ADVA. “A ruggedized design and minimal visibility make our OSA 5405-MB easy to install in almost any outdoor location. With the power to compensate for ionospheric delay variations and provide resilience against jamming and spoofing, our compact edge solution really is the key to 5G synchronization.”
The OSA 5405 Series is a uniquely versatile timing solution ideal for deployment deep in urban canyons, precisely where the most advanced end applications require stringent synchronization. With its small form factor, the OSA 5405-I indoor variant can be positioned on windows to avoid multipath signal interference. Offering both electrical and optical interfaces and featuring cost-effective Ethernet cabling, the OSA 5405 Series avoids the archaic and expensive RF feeds of traditional GNSS installations by integrating an antenna, GNSS receiver and PTP grandmaster in a single device.
Now with multi-band GNSS technology, the OSA 5405-MB also protects against timing inaccuracies caused by ionospheric disturbance. By receiving GNSS signals in two frequency bands and using the differences between them to calculate and compensate for delay variation, the OSA 5405-MB eliminates inaccuracy and ensures ultra-precise synchronization whatever the space weather conditions. It can also work with up to four concurrent GNSS constellations (GPS, GALILEO, GLONASS and BEIDOU), increasing the number of observable satellites in urban canyons. A comprehensive set of Syncjack™ PTP and GNSS jamming and spoofing monitoring features in combination with ADVA’s Ensemble Controller and Sync Director assures highest synchronization quality and provides transparency for simple operation of even very large synchronization networks. The OSA 5405-MB also offers network-delivered timing backup to further mitigate GNSS vulnerabilities and make synchronization more robust and resilient.
“Highly accurate timing is becoming more critical every year. In CSP infrastructure, power utilities, broadcast and enterprise networks across most industries, precision synchronization that meets tight PRTC-B specifications is essential. The OSA 5405-MB is capable of providing different PTP profiles as well as NTP directly out of the smart antenna with no compromise on accuracy,” commented Nir Laufer, VP, product line management, Oscilloquartz, ADVA. “With its multi-band receiver, our new OSA 5405-MB delivers PRTC-B levels of synchronization accuracy. Small, lightweight, low-power and versatile, it can be deployed almost anywhere and will perform perfectly even under extreme conditions. What’s more, its Syncjack™ PTP and GNSS assurance capabilities ensure accurate, real-time monitoring of timing quality.”
Further information on the OSA 5405-MB is available in these slides: https://adva.li/osa-5405-mb-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005060/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
